Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
featured
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

This is an open-label, monotherapy study of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement.  Subjects will receive a once daily (QD) dose of INCB054828 at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule.  With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will …

myeloid neoplasm
FGFR1
lymphoid malignancy
  • 80 views
  • 14 Dec, 2020
  • 35 locations
Study of Magrolimab Combinations in Participants With Myeloid Malignancies

The primary objectives of this study are to evaluate the safety, tolerability and to determine the recommended Phase 2 dose (RP2D) of magrolimab (Mag) in combination with the anti-leukemia therapies of venetoclax (Ven) and azacitidine (Aza) (Cohort 1), mitoxantrone, etoposide, and cytarabine (MEC) (Cohort 2) and CC-486 (Cohort 3) respectively …

  • 0 views
  • 01 Sep, 2021
  • 2 locations
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies.

  • 0 views
  • 27 Aug, 2021
  • 33 locations
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

This research study is studying a drug as a possible treatment for IDH1-mutant myeloid neoplasms. -The drug involved in this study is ivosidenib (AG-120)

  • 21 views
  • 26 Jan, 2021
  • 3 locations
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

The purpose of this First-in-Human Phase 1 study is to determine if AMG 330 given as a continuous IV infusion is safe and tolerable in adult subjects that have myeloid malignancies, and to

leukemia
acute promyelocytic leukemia
refractory acute myeloid leukemia (aml)
cancer
  • 0 views
  • 11 Jul, 2021
  • 19 locations
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

The use of genomics and functional translational studies is to identify and diagnose patients with precursor features of myeloid neoplasms and inherited bone marrow failure syndromes.

  • 0 views
  • 19 Mar, 2021
  • 1 location
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Another term for myelodysplastic syndrome is bone marrow failure. The bone marrow is where components of blood such as red cells, platelets and white cells are made. In bone marrow failure, the ability for bone marrow to make these cells is decreased. In myelodysplastic syndrome, this decreased bone marrow function …

myeloproliferative disorder
colony stimulating factor
hemolysis
anemia
bone marrow procedure
  • 0 views
  • 25 Aug, 2021
  • 1 location
A Study of BGB-11417 in Participants With Myeloid Malignancies

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

myeloid leukemia
leukemia
azacitidine
  • 0 views
  • 12 Sep, 2021
  • 16 locations
ATG/PTCy in Haplo-PBSCT Randomized Controlled Multi-center

A novel regimen, which is composed of a low dose of ATG (5 mg/kg) and low-dose PTCy (one dose of PTCy, 50mg/kg) for GvHD prophylaxis in Haplo-PBSCT for patients with hematologic malignancies, was designed to decrease the risk of aGvHD and lower the incidence of virus reactivation.

  • 0 views
  • 22 Jan, 2021
  • 5 locations
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD

  • 0 views
  • 26 Jan, 2021
  • 1 location